Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
5 drugs for “Metastatic Pancreatic Ductal Adenocarcinoma”
Approved 1
- RelacorilantCORCEPT THERAPEUTICS INCMetastatic Pancreatic Ductal Adenocarcinoma · next catalyst 17 Dec 2026
Phase 3 3
- NIS793NOVARTIS AGMetastatic Pancreatic Ductal Adenocarcinoma
- QuemliclustatArcus Biosciences, Inc.Metastatic Pancreatic Ductal Adenocarcinoma
- Telisotuzumab adizutecanAbbVie Inc.Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2/3 1
- PonsegromabPFIZER INCMetastatic Pancreatic Ductal Adenocarcinoma
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.